Repeatability and Reproducibility of the CADence™System

Coronary Artery Disease Clinical Trial

— SEQUEL  

Official title:

Repeatability and Reproducibility of the CADence™System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03793049
• Other study ID #: 1030-002-03
• Status: Completed
• Start date: January 23, 2019
• Est. completion date: June 26, 2019

Study information

• Verified date: January 2019
• Source: AUM Cardiovascular, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is designed as a prospective study to capture data for evaluating the repeatability and reproducibility of the CADence™ System. The study will be conducted at 3 different study sites using 6 CADence™ systems. Each subject will be tested 4 separate times by 2 different operators at each site and will be tested at all 3 site locations in order to accomplish this evaluation. The study will enroll a total of at least 24 CADence positive patients and at least 24 CADence negative patients.

Description:

The CADence™ system is comprised of a digital stethoscope used to record cardiac (heart) sounds, with integrated sensor used to record electrical activity of the heart (ECG), a single‐use patient booklet, and the CADence™ Software application. CADence™ Software is a clinical decision support tool for the noninvasive functional evaluation of patients presenting with chest pain and at least two coronary artery disease risk factors that is intended to aid a qualified clinician's analysis of normal/physiological and pathological heart murmurs and in ruling out significant coronary disease as a cause for these symptoms of cardiovascular disease, utilizing simultaneous recording of cardiac sounds and ECG.

The purpose of this study is to assess the precision of the CADence site using multiple operators, cadence systems and clinical sites.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: June 26, 2019
• Est. primary completion date: June 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

Subjects clinically indicated for nuclear stress test and who satisfy all the inclusion and exclusion criteria are eligible for participation.

Inclusion criteria:

1. Age 22 years or older

2. Willing and able to give informed consent

3. Clinical indication for nuclear stress test evaluation

4. Chest pain syndrome

5. Two or more coronary artery disease risk factors as defined by:

• Dyslipidemia: LDL >130 mm/dL or HDL <35 mm/dL or on treatment for dyslipidemia

• Hypertension: blood pressure >140 mmHg systolic, >90 mmHg diastolic or on blood pressure altering treatment

• Obesity: BMI>28

• Current cigarette smoking

• Diabetes: Type 1 or 2

• Family history: coronary disease in a first or second degree relative

Exclusion Criteria:

• Subjects clinically indicated for nuclear stress test and who satisfy all the inclusion and exclusion criteria are eligible for participation.

Inclusion criteria:

1. Age 22 years or older

2. Willing and able to give informed consent

3. Clinical indication for nuclear stress test evaluation

4. Chest pain syndrome

5. Two or more coronary artery disease risk factors as defined by:

• Dyslipidemia: LDL >130 mm/dL or HDL <35 mm/dL or on treatment for dyslipidemia

• Hypertension: blood pressure >140 mmHg systolic, >90 mmHg diastolic or on blood pressure altering treatment

• Obesity: BMI>28

• Current cigarette smoking

• Diabetes: Type 1 or 2

• Family history: coronary disease in a first or second degree relative

Exclusion criteria:

1. Body Mass Index (BMI)<18.5 or BMI >40

2. Known coronary disease as defined as:

• Prior bypass surgery or coronary stenting

• Q-wave infarction on a past EKG (>0.01 sec Q-wave duration in two adjacent leads)

3. Presence of pacemaker/defibrillator

4. Presence of artificial valve

5. Presence of obvious cyanotic or pre-diagnosed congenital heart defect and coarctation of the aorta

6. The presence of murmurs including moderate to severe valve disease, ventricular septal defects, and AV fistulae

7. Presence of moderate or severe valve disease as defined by >1/6 heart murmur on physical diagnosis

8. Left Ventricular Assist Device (LVAD)

9. Presence of scars on the site thorax areas

10. Participation in trial within 30 days prior to collecting CADenceTM data except participation in registry studies

11. Asthma with wheezing

12. Inability to lie flat in the supine position

13. Acute coronary syndrome with elevated cardiac biomarkers (TP>3x upper limit of normal (ULN) or CKMB>3x ULN)

14. Heart transplant

15. Current cocaine use (within the past 24 hours, as reported by subject)

16. Chronic Obstructive Pulmonary Disease (COPD)

17. Patient is not an acceptable candidate for CT angiography:

• Renal failure with GFR <50

• Iodinated contrast allergy

• Elevated heart rate which cannot be controlled sufficiently to achieve a good CT angiogram

• Body weight >350lbs

• Persistent sinus rhythm abnormalities (e.g., atrial fibrillation) based on medical history.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• CADence testing will be performed
CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software

Locations

Country	Name	City	State
United States	910 Medical	Minneapolis	Minnesota
United States	Northfield Urgent Care Clinic	Northfield	Minnesota
United States	Pivot Point Medical	Northfield	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
AUM Cardiovascular, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernández-Golfín C, Rincón LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Mäki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging. 2015 Mar;8(3). pii: e002179. doi: 10.1161/CIRCIMAGING.114.002179. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive Percent Agreement and Negative Percent Agreement	repeatability and reproducibility	14 days